(Reuters) – Amazon.com Inc stated on Thursday it might purchase small on-line pharmacy PillPack, a transfer that may put the world’s greatest on-line retailer in direct competitors with drugstore chains, drug distributors and pharmacy profit managers.

The deal’s potential to disrupt main gamers throughout the drug provide chain nationwide prompted a sell-off in shares of attainable rivals, whereas sending Amazon shares up 2.5 p.c.

PillPack provides pre-sorted prescribed drugs and different companies to individuals who take a number of medicines, a rising market because the U.S. inhabitants ages and requires remedy for a number of advanced, continual circumstances.

Amazon is vying for a share of what’s a greater than $450 billion complete U.S. prescription drug market, in line with analysis agency IQVIA. Though PillPack expects gross sales to exceed solely about $100 million this yr, Amazon’s enormous buyer base and current delivery infrastructure may enable the corporate to scale up rapidly.

Amazon may additionally negotiate immediately with pharmaceutical firms, giving them the power to supply low-cost generic medicine even to prospects with out medical insurance, in line with business consultants. However it’ll face deeply entrenched competitors dominated by pharmacies run by CVS Well being, Walgreen Boots Alliance and Walmart Inc, and pharmacy advantages offered by CVS, Categorical Scripts UnitedHealth Group.

“Amazon’s acquisition of PillPack is a warning shot in what’s about to turn out to be a serious battle inside the pharmacy area,” stated Neil Saunders, managing director of GlobalData Retail.

The worth of the deal was not disclosed. Bloomberg reported it to be $1 billion, citing an individual conversant in the matter.

Pharmacy chains and drug wholesalers misplaced about $14 billion in market worth on Thursday, whereas Amazon gained about $5.5 billion.

Shares of CVS closed down 6.1 p.c, whereas Walgreen fell 10 p.c. Shares of drug wholesalers McKesson Corp, Cardinal Well being and AmerisourceBergen all fell.


The information comes only a week after a three way partnership of Amazon, Berkshire Hathaway Inc and JPMorgan Chase & Co named a CEO who might be tasked with considerably reducing healthcare prices for its estimated 1 million workers and dependents.

Though brick-and-mortar shops may really feel the consequences of Amazon’s competitors, the largest battles will possible be fought by mail-order pharmacies, which typically serve sufferers with continual circumstances reminiscent of diabetes and coronary heart illness which will require medicine to manage blood stress, ldl cholesterol and different issues.

PillPack stated it has tens of 1000’s of consumers throughout the nation. However its expectation of over $100 million in 2018 income pales in contrast with bigger rivals. CVS final yr had about $45.7 billion in income from its mail order pharmacy enterprise, accounting for about 15 p.c of its pharmacy claims.

Pharmacy profit managers (PBMs) negotiate prescription drug pricing for employers and well being plans and run massive mail-order pharmacies, providing incentives to sufferers to fill prescriptions with them.

Docs and PBMs have lengthy stated sufferers not correctly taking their medicines is without doubt one of the major causes of elevated healthcare prices, resulting in hospitalizations and extra extreme well being points. Firms like PillPack and Categorical Scripts that supply care administration companies to enhance affected person compliance are seen as more and more essential in serving to management rising prices.

With Amazon’s announcement Mizuho analyst Ann Hynes, in a be aware, stated pending well being insurer/PBM mergers of Aetna Inc with CVS and Cigna Corp with Categorical Scripts “are much more crucial now.”


Walgreen CEO Stefano Pessina, on a convention name after reporting quarterly outcomes, stated he was “not notably anxious” in regards to the PillPack deal.

“The pharmacy world is rather more advanced than simply delivering sure capsules or sure packages,” Pessina stated.

An indication marks the company places of work of PillPack in Somerville, Massachusetts, U.S., June 28, 2018. REUTERS/Brian Snyder

That stated, Pessina added, “We all know that we’ve to vary the extent of our companies to the purchasers, and we’re working fairly exhausting on that path.”

Some analysts performed down the speedy risk.

“I consider they purchased this to be taught in regards to the market and to find out if they can make bigger investments,” stated Morningstar analyst Vishnu Lekraj.

Cantor Fitzgerald analyst Steven Halper famous that PBMs usually require well being plan members to make use of their very own mail order pharmacies.

He stated PillPack may very well be kicked out of present PBM networks, “particularly if Amazon has designs of considerably ramping its prescription quantity.”

Categorical Scripts dropped PillPack from its community in April 2016, alleging that it had misrepresented itself as a retail pharmacy. The 2 reached an settlement a month later.

PillPack holds pharmacy licenses in all 50 states. It’s an in-network pharmacy for some PBMs and for main Medicare Half D plans, a federal drug profit to assist Medicare beneficiaries pay for self-administered prescription medicines.

PillPack had attracted curiosity from Walmart Inc, which was trying to purchase it for lower than $1 billion, CNBC reported in April. The Amazon deal is predicted to shut throughout the second half of 2018.

To view a graphic on Amazon disrupts the well being and pharmacy area, click on: reut.rs/2tCLjss

Slideshow (2 Pictures)

Reporting by Sonam Rai and Ankur Banerjee in Bengaluru; further reporting by Ben Hirschler in London and Michael Erman and Jilian Mincer in New York, writing by Invoice Berkrot; Enhancing by Anil D’Silva, Invoice Rigby and Richard Chang